Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02873364
Other study ID # 93-01-01-8312
Secondary ID
Status Recruiting
Phase Phase 3
First received August 11, 2016
Last updated August 16, 2016
Start date August 2016
Est. completion date January 2017

Study information

Verified date August 2016
Source Shiraz University of Medical Sciences
Contact Keramatallah Jahanshahi, MD
Phone +989177416523
Email kjahanshahi91@gmail.com
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

Chronic spontaneous urticaria is an inflammatory disease which is characterized with intermittent or daily urticaria. This diseases lasts for more than 6 weeks. Several recent studies have suggested a role for vitamin D in modulation of immune system and pathogenesis of chronic urticaria.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Uriticaria or angioedema daily or more than 3 days a weeks for at least 6 weeks

Exclusion Criteria:

- Physical urticaria aquired or hereditary angioedema Calcium level > 10.3 mg/dl Glomerular filtration rate <50 Sarcoidosis Primary hyperparathyroidism Granulomatous diseases Malignancies Pregnancy Lactation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D3 (High dose)
Daily 4000 unites vitamin D
Vitamin D3 (Low dose)
Daily 600 unites vitamin D

Locations

Country Name City State
Iran, Islamic Republic of Shiraz University of Medical Sciences Shiraz Fars

Sponsors (1)

Lead Sponsor Collaborator
Shiraz University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urticaria symptom severity questionnaire after 1 week Urticaria Symptom Severity ranging from 0 to 93 1 weeks No
Secondary Urticaria symptom severity questionnaire after 6 week Urticaria Symptom Severity ranging from 0 to 93 6 weeks No
Secondary Urticaria symptom severity questionnaire after 12 week Urticaria Symptom Severity ranging from 0 to 93 12 weeks No
See also
  Status Clinical Trial Phase
Terminated NCT03693625 - A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study Phase 2
Recruiting NCT03545464 - COrticosteroids in acUte uRticAria in emerGency dEpartment Phase 3
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Terminated NCT00069329 - Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease N/A
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Terminated NCT00199238 - Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria Phase 2
Completed NCT02576041 - Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Phase 4
Completed NCT02238249 - Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria N/A
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT03296358 - Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department. N/A
Completed NCT00130234 - Effect of Anti-IgE in Chronic Urticaria Phase 2
Completed NCT00795158 - How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) Phase 3
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Completed NCT02424799 - Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 Phase 1
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT00751218 - A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Phase 4
Completed NCT03137069 - A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). Phase 2
Recruiting NCT05115136 - Using Doxepin for Urticaria Phase 3